Last reviewed · How we verify
NCT06191796
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
Phase 1 trial testing zanzalintinib in Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors in 25 participants. Terminated before completion.
12 May 2025
Quick facts
| Lead sponsor | Exelixis |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 25 January 2024 |
| Primary completion | 12 May 2025 |
| Estimated completion | 12 May 2025 |
| Sites | 14 locations across United States |
Drugs / interventions tested
- zanzalintinib — full drug profile →
- AB521 — full drug profile →
- Nivolumab (nivolumab) — full drug profile →
Conditions studied
- Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors — all drugs for Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors →
Sponsor
Exelixis — full company profile →
Who can join
18 and older, any sex, with Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn about the safety and preliminary antitumor activity of zanzalintinib in combination with AB521 (doublet) and in combination with AB521 plus nivolumab (triplet) in participants with advanced ccRCC or other advanced solid tumors. The main questions it aims to answer are: * The recommended doses (RDs) * The safety and tolerability * The PK and the preliminary efficacy
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06191796
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Exelixis trials
Trials by the same sponsor.
- NCT06630247 — A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid · Phase 1 · terminated
- NCT06545331 — Study of XB010 in Subjects With Solid Tumors · Phase 1 · recruiting
- NCT05932862 — A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors · Phase 1 · recruiting
- NCT05144347 — Study of XL114 in Subjects With Non-Hodgkin's Lymphoma · Phase 1 · terminated
- NCT05176483 — Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06191796 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Exelixis
- Last refreshed: 12 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06191796.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing